Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,840 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+ - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Long Beach, CaliforniaAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT07137416RecruitingPhase 1
Combination drug study for HER2-positive breast and other cancers
This study tests a new combination of two anti-cancer drugs (CX-5461 and T-DXd) for people with HER2-positive breast cancer or other solid tumors. It aims to see if the combination is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT05687123RecruitingPhase 1
Adding sunitinib to Lutathera for pancreatic neuroendocrine tumors
This early-phase study tests whether adding sunitinib (a targeted pill) to Lutathera (a radioactive treatment) works better for people with advanced pancreatic neuroendocrine tumors. It also checks safety, since this combination has not been widely studied yet.
Duarte, CaliforniaAges 18 years+ - NCT05136196RecruitingPhase 2
Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer
This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.
Phoenix, ArizonaAges 18 years+ - NCT01174121RecruitingPhase 2
Immunotherapy made from your tumor-fighting immune cells
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.
Bethesda, MarylandAges 18–72 - NCT05910827RecruitingPhase 1/Phase 2
Study of a HER3 antibody with cetuximab and possibly docetaxel
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Sydney, New South WalesAges 18 years+ - NCT07124611Recruiting
Emotional support study for pancreatic cancer patients
This study offers a brief psychological intervention to help patients with pancreatic cancer manage emotional well-being before surgery. It is designed for newly diagnosed patients who are starting chemotherapy before surgery.
Columbus, OhioAges 18 years+ - NCT07066995RecruitingPhase 1/Phase 2
Dual-target CAR-T cell therapy for advanced pancreatic cancer
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
Beijing, Beijing MunicipalityAges 21–90 - NCT05040360RecruitingPhase 2
Chemotherapy after surgery for high-risk pancreatic NET tumors
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
Anchorage, AlaskaAges 18 years+ - NCT04406831Recruiting
Testing microRNA for pancreatic cancer diagnosis and treatment response
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Norwalk, ConnecticutAges 18 years+ - NCT05714124Recruiting
Testing liver procedures to treat tumors when surgery isn’t possible
This trial studies different ways to place treatments inside the liver to control liver tumors when they can’t be removed with surgery or ablation. It may help certain people by improving how well the tumor is treated while keeping liver function safer.
MilanAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT04982276RecruitingPhase 1/Phase 2
Test new cancer drugs for advanced stomach or esophagus cancer
This Phase 1/2 study tests the safety and effectiveness of two investigational drugs (AK109 and AK104) in people with advanced stomach (or lower esophagus/GEJ) cancer. It’s for cases where the cancer did not respond to first-line treatment that included anti–PD-1/PD-L1 therapy plus chemotherapy.
BeijingAges 18–75 - NCT05691465RecruitingPhase 2
Radiation drug for metastatic prostate cancer with neuroendocrine cells
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
Duarte, CaliforniaAges 18 years+ - NCT05113537RecruitingPhase 1/Phase 2
Abemaciclib before PSMA cancer therapy for advanced prostate cancer
This trial tests whether taking abemaciclib before a PSMA-targeted radioligand can help people with advanced, treatment-resistant prostate cancer. The goal is to improve how well the PSMA therapy works while staying safe.
San Francisco, CaliforniaAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT03334708Recruiting
Blood test study for pancreatic cancer
This study looks at blood tests to find markers that may help detect and monitor pancreatic cancer. It compares people with pancreatic cancer to those with benign pancreatic conditions and healthy volunteers.
Middletown, New JerseyAges 18 years+ - NCT07715747RecruitingPhase 1
TJ037130 for advanced solid tumors
This trial tests an investigational drug called TJ037130 in people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment is available. The drug targets a protein called Claudin 6 on tumor cells and may help your immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05620732Recruiting
CAR-T treatment for advanced stomach or pancreatic cancer
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
Shenzhen, GuangdongAges 18–75 - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT07755436RecruitingPhase 1
Study of ARR-002 for advanced ovarian or endometrial cancer
This study tests an experimental drug called ARR-002 in people with advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to standard treatments. The goal is to see if it is safe and whether it shrinks tumors.
Orlando, FloridaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,840 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.